AIVEN
29.11.2022 09:02:41 CET | Business Wire | Press release
Aiven, the open source cloud data platform company, has announced several key senior leadership appointments who collectively are focused on helping deliver the company’s commitment to democratising access to the best open source technologies while reducing the environmental impact of cloud services.
These strategic new leadership roles span operations and strategy, product marketing, developer relations, and product management and include
- Katariina Korhonen, Vice President of Strategy and Operations
- Amy Krishnamohan, Vice President of Product Marketing
- Ian Massingham, Vice President of Developer Relations and Community
- Jonah Kowall, Vice President of Product Management
Oskari Saarenmaa, CEO and Co-founder at Aiven, comments on the appointments. “Aiven’s mission is to make developers’ lives better, by helping them build more sophisticated applications accessible to all. When starting Aiven, our goal was to build the company that we wanted to work for. Today we are delighted to be welcoming such a talented group to our leadership team and our wider Aiven community. Our ability to attract the best talent, while also supporting the career growth of our people continues to be instrumental in helping us develop new platform capabilities that bring us closer towards our goal of building more sustainable applications in the cloud.”
Katariina Korhonen has been appointed Vice President of Strategy and Operations to Aiven's Executive Leadership team. Katariina works closely with other senior executives and the board of directors and is focusing on building out Aiven’s corporate, operations, and sustainability strategy globally. Prior to her new role, Katariina spent the last six years in various executive roles at Smartly.
Amy Krishnamohan has also joined as Vice President of Product Marketing with the responsibility for Aiven’s product marketing direction and strategy, and nurturing and engaging with key stakeholders such as analysts, industry thought leaders, and strategic customers to increase the market awareness of Aiven. A Masters alumna of Carnegie Mellon University, Amy has gained diverse experience across product marketing and marketing strategy where she managed open-source database projects and other cloud-native databases. Prior to joining Aiven, she led product marketing strategies from major database companies such as MariaDB and Google Cloud.
Aiven also welcomes Ian Massingham as the company’s Vice President of Developer Relations and Community focusing on further building Aiven’s relationship with the developer community and ensuring that our programs align with our mission of making developers’ lives better. Prior to joining Aiven, Ian led the Developer Relations & Community team at MongoDB. Before that, he played an integral role in establishing and scaling the evangelism and developer relations function at AWS and led Worldwide Solutions Architecture for Startup customers for the final 18 months of his tenure at AWS.
Jonah Kowall has also joined as Aiven’s new Vice President of Product Management. In his role, Jonah will lead and execute the product strategy and head the product team responsible for platform enhancements to support ongoing growth in Aiven’s customer base. Previously a Chief Technology Officer at Logz.io and several other startups, Jonah’s background includes being a Research VP at Gartner and a regular contributor and maintainer of the Open Source Jaeger and OpenTelemetry projects. Jonah joins Aiven and brings with him a wealth of knowledge on all things “observability”.
This latest announcement of senior leadership expansion closely follows the appointment of Olivier van Grembergen as Regional Vice President (RVP) of Aiven Asia Pacific (APAC), announced earlier in October to drive continued growth in the region.
To learn more about Aiven, please visit https://aiven.io/
Free Trial https://console.aiven.io/signup
About Aiven
Headquartered in Helsinki and with hubs in Berlin, Boston, Paris, Singapore, Sydney, Tokyo, and Toronto, Aiven provides managed open source data technologies, like PostgreSQL, Apache Kafka and OpenSearch, on all major clouds. Through Aiven, developers can do what they do best: create applications. Meanwhile, Aiven does what they do best: manage cloud data infrastructure. Aiven enables customers to drive business results from open source that trigger true transformations far beyond their own backyard. Most recently, Aiven achieved a $3B valuation and has now raised $420M total funding backed by its investors Atomico, Earlybird, Eurazeo, IVP, Lifeline, Salesforce Ventures, and World Innovation Lab.
To learn more about Aiven, visit aiven.io and follow @aiven_io on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom